{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:51:49Z","timestamp":1794865909125,"version":"4.9.1"},"reference-count":76,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>NAMI-A (ImH)[trans-RuCl4(dmso-S)(Im)], where dmso-S = sulfur-bonded dimethyl sulfoxide and Im = imidazole emerged as a promising alternative to approved Pt(II) anticancer drugs, offering high antimetastatic activity and low toxicity. However, its development was discontinued due to insufficient activity against primary tumors. In this work, we synthesized 12 new pyridine NAMI derivatives and evaluated their anticancer activity against three cancer cell lines: lung adenocarcinoma A549, melanoma MeWo and bladder cancer T24, and compared with the nonmalignant keratinocyte HaCaT cells. Among them, two complexes exhibited potent cytotoxicity and selectivity while retaining the characteristic antimetastatic activity of the NAMI scaffold. The Ru(III) complex (CHO-PyH)[trans-Ru(CHO-Py)Cl4 (dmso-S)], where CHO-Py = pyridine-3-aldehyde, displayed an IC50 of 34 \u03bcM and a selectivity index of 7.60 against A549 cells. Additionally, (NCS-PyH)[trans-RuCl4(dmso-S)(NCS-Py)], where NCS-Py = 3-(isothiocyanatomethyl)pyridine, showed an IC50 of 240 nM and a selectivity index of 5.2 against T24 cells.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c03490","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:17:52Z","timestamp":1784827072000},"page":"17881-17895","source":"Crossref","is-referenced-by-count":2,"title":["New Ru(III)\nNAMI\/NAMI-A Analogue Complexes\nwith Selective Anticancer Activity"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3423-4487","authenticated-orcid":true,"given":"Manel","family":"Estruch-Blasco","sequence":"first","affiliation":[{"name":"Universidad de Sevilla , , c\/Profesor Garci\u0301a Gonza\u0301lez, 2 , ,","place":["Sevilla, Spain, 41012"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Caldero\u0301n-Montan\u0303o","sequence":"additional","affiliation":[{"name":"Universidad de Sevilla , , c\/Profesor Garci\u0301a Gonza\u0301lez, 2 , ,","place":["Sevilla, Spain, 41012"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-8459","authenticated-orcid":true,"given":"Eleuterio","family":"A\u0301lvarez","sequence":"additional","affiliation":[{"name":"CSIC-Universidad de Sevilla , , avda. Ame\u0301rico Vespucio 49 , ,","place":["Sevilla, Spain, 41092"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-7978","authenticated-orcid":true,"given":"Antonio","family":"Sa\u0301nchez-Coronilla","sequence":"additional","affiliation":[{"name":"Universidad de Sevilla , , c\/Profesor Garci\u0301a Gonza\u0301lez, 2 , ,","place":["Sevilla, Spain, 41012"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Lo\u0301pez-La\u0301zaro","sequence":"additional","affiliation":[{"name":"Universidad de Sevilla , , c\/Profesor Garci\u0301a Gonza\u0301lez, 2 , ,","place":["Sevilla, Spain, 41012"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-0574","authenticated-orcid":true,"given":"Manuel","family":"Pernia Leal","sequence":"additional","affiliation":[{"name":"Universidad de Sevilla , , c\/Profesor Garci\u0301a Gonza\u0301lez, 2 , ,","place":["Sevilla, Spain, 41012"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"5","key":"2026081311080494300_cit1","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The Next Generation of Platinum Drugs:\nTargeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem. Rev."},{"issue":"5","key":"2026081311080494300_cit2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1021\/ar100140e","article-title":"Metal Complexes as DNA Intercalators","volume":"44","author":"Liu","year":"2011","journal-title":"Acc. Chem. Res."},{"issue":"16","key":"2026081311080494300_cit3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1039\/b601840h","article-title":"Metal-based antitumour drugs in the post genomic era","author":"Dyson","year":"2006","journal-title":"Dalton Trans."},{"issue":"3","key":"2026081311080494300_cit4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/inorganics7030031","article-title":"Designing\nRuthenium Anticancer Drugs: What Have We Learnt from the Key Drug\nCandidates?","volume":"7","author":"Coverdale","year":"2019","journal-title":"Inorganics"},{"issue":"4","key":"2026081311080494300_cit5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00775-007-0337-4","article-title":"Ruthenium(III) dimethyl\nsulfoxide pyridinehydroxamic\nacid complexes as potential antimetastatic agents: synthesis, characterisation\nand in vitro pharmacological evaluation","volume":"13","author":"Griffith","year":"2008","journal-title":"JBIC,\nJ. Biol. Inorg. Chem."},{"issue":"3","key":"2026081311080494300_cit6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10637-016-0337-8","article-title":"Molecular\nmode of\naction of NKP-1339\u2500a clinically investigated ruthenium-based\ndrug\u2500involves ER- and ROS-related effects in colon carcinoma\ncell lines","volume":"34","author":"Flocke","year":"2016","journal-title":"Invest. New Drugs"},{"issue":"6","key":"2026081311080494300_cit7","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000154","article-title":"Safety and activity\nof IT-139, a\nruthenium-based compound, in patients with advanced solid tumours:\na first-in-human, open-label, dose-escalation phase I study with expansion\ncohort","volume":"1","author":"Burris","year":"2016","journal-title":"ESMO Open"},{"key":"2026081311080494300_cit8","unstructured":"A Phase 1b\/2a Dose Escalation Study of BOLD-100\nin Combination with\nFOLFOX Chemotherapy in Patients with Advanced Solid Tumours. https:\/\/clinicaltrials.gov\/study\/NCT04421820(NCT04421820) (accessed\nMay 29, 2026)."},{"key":"2026081311080494300_cit9","unstructured":"A Phase 1b Trial\nof BOLD-100 plus Doxorubicin in Advanced Soft Tissue\nSarcomas. https:\/\/clinicaltrials.gov\/study\/NCT07027423(NCT07027423) (accessed May 29, 2026)."},{"issue":"32","key":"2026081311080494300_cit10","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1039\/C4DT01356E","article-title":"NAMI-A is highly cytotoxic toward\nleukaemia cell lines: evidence of inhibition of KCa 3.1 channels","volume":"43","author":"Pillozzi","year":"2014","journal-title":"Dalton Trans."},{"key":"2026081311080494300_cit11","doi-asserted-by":"publisher","DOI":"10.1515\/9783110470734-005","article-title":"The Deceptively\nSimilar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different\nActions. What Did We Learn in the Past 30 Years?","volume-title":"Metallo-Drugs: Development and Action of Anticancer Agents","author":"Alessio","year":"2018"},{"issue":"1","key":"2026081311080494300_cit12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase\nI\/II study with ruthenium compound NAMI-A and\ngemcitabine in patients with non-small cell lung cancer after first\nline therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"4","key":"2026081311080494300_cit13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1134\/S0036023621030177","article-title":"Ruthenium(III)\nComplexes of NAMI-A Type with Ligands Based on Lonidamine and Bexarotene\nas Antiproliferative Agents","volume":"66","author":"Shutkov","year":"2021","journal-title":"Russ. J. Inorg.\nChem."},{"issue":"13","key":"2026081311080494300_cit14","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1021\/acs.inorgchem.5b00802","article-title":"Synthesis\nand Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic-Acid-Modified\nPyridine and Triphenylphosphine Ligands","volume":"54","author":"Agonigi","year":"2015","journal-title":"Inorg.\nChem."},{"issue":"4","key":"2026081311080494300_cit15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.17344\/acsi.2017.3844","article-title":"Synthesis and X-ray Structural Analysis\nof the Ruthenium(III) Complex Na[trans-RuCl4(DMSO) (PyrDiaz)], the\nDiazene Derivative of Antitumor NAMI-Pyr","volume":"64","author":"Vajs","year":"2017","journal-title":"Acta\nChim. Slov."},{"key":"2026081311080494300_cit16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejmech.2014.02.062","article-title":"Novel ruthenium\ncomplexes ligated with 4-anilinoquinazoline derivatives: Synthesis,\ncharacterisation and preliminary evaluation of biological activity","volume":"77","author":"Ji","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"2026081311080494300_cit17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/acs.inorgchem.5b02109","article-title":"Induction\nof Cytotoxicity in Pyridine Analogues\nof the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization","volume":"55","author":"Mu","year":"2016","journal-title":"Inorg. Chem."},{"issue":"5","key":"2026081311080494300_cit18","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ma402078d","article-title":"Superior\nChemotherapeutic\nBenefits from the Ruthenium-Based Anti-Metastatic Drug NAMI-A through\nConjugation to Polymeric Micelles","volume":"47","author":"Blunden","year":"2014","journal-title":"Macromolecules"},{"issue":"14","key":"2026081311080494300_cit19","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1016\/j.biomaterials.2012.01.057","article-title":"Ruthenium-based complex nanocarriers for cancer therapy","volume":"33","author":"Mangiapia","year":"2012","journal-title":"Biomaterials"},{"key":"2026081311080494300_cit20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/ejoc.201600943","article-title":"Ru III Complexes\nfor Anticancer Therapy: The Importance of Being Nucleolipidic","volume":"2017","author":"Riccardi","year":"2017","journal-title":"Eur. J. Org. Chem."},{"issue":"1","key":"2026081311080494300_cit21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1021\/acsbiomaterials.7b00547","article-title":"\u201cDressing\nup\u201d an Old Drug: An Aminoacyl Lipid for the Functionalization\nof Ru(III)-Based Anticancer Agents","volume":"4","author":"Riccardi","year":"2018","journal-title":"ACS Biomater.\nSci. Eng."},{"key":"2026081311080494300_cit22","doi-asserted-by":"publisher","first-page":"213016","DOI":"10.1016\/j.bioadv.2022.213016","article-title":"Bioengineered\nlipophilic Ru(III) complexes as potential anticancer agents","volume":"139","author":"Riccardi","year":"2022","journal-title":"Biomater. Adv."},{"issue":"7","key":"2026081311080494300_cit23","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.3390\/ijms24076473","article-title":"Triple Negative\nBreast Cancer Preclinical\nTherapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem","volume":"24","author":"Ferraro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"2026081311080494300_cit24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s007750000203","article-title":"Hydrolysis of the tumor-inhibiting\nruthenium(III) complexes\nHIm trans-[RuCl4(im)2] and HInd. trans-[RuCl4(ind)2] investigated\nby means of HPCE and HPLC-MS","volume":"6","author":"Ku\u0308ng","year":"2001","journal-title":"J. Biol. Inorg.\nChem."},{"issue":"11","key":"2026081311080494300_cit25","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-03-0746","article-title":"A Phase\nI and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate,\na Novel Ruthenium Anticancer Agent","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin. Cancer\nRes."},{"issue":"2","key":"2026081311080494300_cit26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1021\/ic202029e","article-title":"Pyridine Analogues of the Antimetastatic Ru(III) Complex\nNAMI-A Targeting Non-Covalent Interactions with Albumin","volume":"51","author":"Webb","year":"2012","journal-title":"Inorg. Chem."},{"issue":"14","key":"2026081311080494300_cit27","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.1021\/acs.inorgchem.1c01441","article-title":"Insights into\nthe Protein Ruthenation Mechanism by Antimetastatic Metallodrugs:\nHigh-Resolution X-ray Structures of the Adduct Formed between Hen\nEgg-White Lysozyme and NAMI-A at Various Time Points","volume":"60","author":"Chiniadis","year":"2021","journal-title":"Inorg. Chem."},{"issue":"14","key":"2026081311080494300_cit28","doi-asserted-by":"publisher","first-page":"10124","DOI":"10.1021\/acs.jmedchem.1c00360","article-title":"Importance\nof Hydrogen Bonding: Structure-Activity Relationships of Ruthenium(III)\nComplexes with Pyridine-Based Ligands for Alzheimer\u2019s Disease\nTherapy","volume":"64","author":"Wall","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026081311080494300_cit29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1039\/d0mt00054j","article-title":"Ruthenium(iii) complexes\ncontaining thiazole-based ligands that modulate amyloid-\u03b2 aggregation","volume":"12","author":"Huffman","year":"2020","journal-title":"Metallomics"},{"issue":"9","key":"2026081311080494300_cit30","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1021\/jm061081y","article-title":"Structure\u2013Activity Relationships for NAMI-A-type\nComplexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = Imidazole,\nIndazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole):\nAquation, Redox Properties, Protein Binding, and Antiproliferative\nActivity","volume":"50","author":"Groessl","year":"2007","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"2026081311080494300_cit31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0009-2797(94)03350-1","article-title":"Effects of ruthenium complexes on\nexperimental tumors: irrelevance of cytotoxicity for metastasis inhibition","volume":"95","author":"Sava","year":"1995","journal-title":"Chem.-Biol. Interact."},{"issue":"10","key":"2026081311080494300_cit32","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/cam4.826","article-title":"Antimetastatic\nactivity of novel ruthenium (III) pyridine complexes","volume":"5","author":"Gu","year":"2016","journal-title":"Cancer Med."},{"issue":"10","key":"2026081311080494300_cit33","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2174\/1389557516666160923125801","article-title":"Roles of Pyridine\nand Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents","volume":"17","author":"Prachayasittikul","year":"2017","journal-title":"Mini Rev. Med. Chem."},{"issue":"5","key":"2026081311080494300_cit34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/cbic.200700586","article-title":"Identification,\nSynthesis, and Enzymology of Non-natural Glucosinolate Chemopreventive\nCandidates","volume":"9","author":"Mays","year":"2008","journal-title":"ChemBioChem"},{"issue":"16","key":"2026081311080494300_cit35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/cmdc.201800348","article-title":"Differentiating\nAntiproliferative\nand Chemopreventive Modes of Activity for Electron-Deficient Aryl\nIsothiocyanates against Human MCF-7 Cells","volume":"13","author":"Anderson","year":"2018","journal-title":"ChemMedChem"},{"key":"2026081311080494300_cit36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mrfmmm.2016.02.005","article-title":"Aldehydes with high and low toxicities\ninactivate cells by damaging distinct cellular targets","volume":"786","author":"Xie","year":"2016","journal-title":"Mutat. Res."},{"issue":"1","key":"2026081311080494300_cit37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.poly.2009.05.082","article-title":"Ruthenium(III) and\niridium(III) complexes with nicotine","volume":"29","author":"Alberti\u0301","year":"2010","journal-title":"Polyhedron"},{"key":"2026081311080494300_cit38","doi-asserted-by":"publisher","first-page":"183097","DOI":"10.1155\/2010\/183097","article-title":"Synthesis and Characterization\nof Novel Ruthenium(III) Complexes\nwith Histamine","volume":"2010","author":"Kljun","year":"2010","journal-title":"Bioinorg. Chem. Appl."},{"issue":"27","key":"2026081311080494300_cit39","doi-asserted-by":"publisher","first-page":"8432","DOI":"10.1021\/jacs.6b02749","article-title":"Interpreting the Paramagnetic NMR Spectra of Potential Ru(III) Metallodrugs:\nSynergy between Experiment and Relativistic DFT Calculations","volume":"138","author":"Novotny\u0301","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"15","key":"2026081311080494300_cit40","doi-asserted-by":"publisher","first-page":"8735","DOI":"10.1021\/acs.inorgchem.7b03233","article-title":"Through-Space Paramagnetic NMR Effects in Host\u2013Guest Complexes:\nPotential Ruthenium(III) Metallodrugs with Macrocyclic Carriers","volume":"57","author":"Chyba","year":"2018","journal-title":"Inorg. Chem."},{"issue":"2","key":"2026081311080494300_cit41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acs.inorgchem.7b02440","article-title":"Hyperfine Effects in Ligand NMR:\nParamagnetic Ru(III) Complexes with 3-Substituted Pyridines","volume":"57","author":"Novotny\u0301","year":"2018","journal-title":"Inorg. Chem."},{"issue":"14","key":"2026081311080494300_cit42","doi-asserted-by":"publisher","first-page":"10185","DOI":"10.1021\/acs.inorgchem.0c01328","article-title":"Zwitterionic Ru(III)\nComplexes: Stability of Metal\u2013Ligand Bond and Host\u2013Guest\nBinding with Cucurbit[7]uril","volume":"59","author":"Malali","year":"2020","journal-title":"Inorg. Chem."},{"issue":"43","key":"2026081311080494300_cit43","doi-asserted-by":"publisher","first-page":"25344","DOI":"10.1039\/D0CP04152A","article-title":"Proton motion inside\n[(DMF)2H]2[W6Cl14]:\nstructural, Raman and luminescence studies","volume":"22","author":"Kolesov","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"3","key":"2026081311080494300_cit44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/molecules25030575","article-title":"Molecular Mechanisms\nof the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables\nin Bladder Cancer","volume":"25","author":"Mastuo","year":"2020","journal-title":"Molecules"},{"key":"2026081311080494300_cit45","doi-asserted-by":"publisher","first-page":"117469","DOI":"10.1016\/j.ejmech.2025.117469","article-title":"Exploring the broad-spectrum activity\nof carbohydrate-based Iberin analogues: From anticancer effect to\nantioxidant properties","volume":"289","author":"Prieto","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"2026081311080494300_cit46","first-page":"5069","article-title":"Tumor-specific cytotoxicity and type\nof cell death\ninduced by benzaldehyde","volume":"30","author":"Ariyoshi-Kishino","year":"2010","journal-title":"Anticancer Res."},{"issue":"15","key":"2026081311080494300_cit47","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1016\/j.ejca.2013.05.018","article-title":"The ruthenium\ncompound KP1339 potentiates the anticancer\nactivity of sorafenib in vitro and in vivo","volume":"49","author":"Heffeter","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"2026081311080494300_cit48","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1039\/D1DT02765D","article-title":"Ru(iii) complexes\nwith pyrazolopyrimidines as anticancer agents: bioactivities and the\nunderlying mechanisms","volume":"51","author":"Gu","year":"2022","journal-title":"Dalton Trans."},{"issue":"3","key":"2026081311080494300_cit49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0959-8049(01)00389-6","article-title":"Influence of chemical stability on the activity of\nthe antimetastasis ruthenium compound NAMI-A","volume":"38","author":"Sava","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"2026081311080494300_cit50","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1046\/j.1432-1327.2000.01121.x","article-title":"A spectroscopic\nstudy of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic\ncomplex, with bovine serum albumin","volume":"267","author":"Messori","year":"2000","journal-title":"Eur. J.\nBiochem."},{"issue":"2","key":"2026081311080494300_cit51","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jinorgbio.2003.12.003","article-title":"The hydrolysis of the\nanti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic\nactivity: an NMR evaluation","volume":"98","author":"Bacac","year":"2004","journal-title":"J. Inorg. Biochem."},{"issue":"6","key":"2026081311080494300_cit52","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1039\/b904071d","article-title":"Recent\ndevelopments in ruthenium\nanticancer drugs","volume":"1","author":"Levina","year":"2009","journal-title":"Metallomics"},{"issue":"25","key":"2026081311080494300_cit53","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1021\/ic00193a060","article-title":"Detailed correlations\nbetween the ligand-to-metal charge-transfer\n(LMCT) spectra of copper(II) and ruthenium(III) imidazoles and imidazolates.\nElectronic structures of carbon-bound ruthenium(III) imidazoles and\nimidazolates","volume":"23","author":"Krogh-Jespersen","year":"1984","journal-title":"Inorg. Chem."},{"issue":"1","key":"2026081311080494300_cit54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1155\/MBD.1994.41","article-title":"Water-Soluble Ruthenium(III)-Dimethyl\nSulfoxide Complexes:\nChemical Behaviour and Pharmaceutical Properties","volume":"1","author":"Mestroni","year":"1994","journal-title":"Met.-Based Drugs"},{"issue":"4","key":"2026081311080494300_cit55","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1039\/C4DT02865A","article-title":"Influence of the binding of reduced\nNAMI-A to human serum albumin on the pharmacokinetics and biological\nactivity","volume":"44","author":"Novohradsky\u0301","year":"2015","journal-title":"Dalton Trans."},{"issue":"6","key":"2026081311080494300_cit56","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1039\/c0dt01168a","article-title":"Control of ligand-exchange processes and the oxidation\nstate of the antimetastatic Ru(iii) complex NAMI-A by interactions\nwith human serum albumin","volume":"40","author":"Webb","year":"2011","journal-title":"Dalton Trans."},{"issue":"2","key":"2026081311080494300_cit57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00432-004-0617-0","article-title":"Heterocyclic complexes\nof ruthenium(III) induce apoptosis in colorectal carcinoma cells","volume":"131","author":"Kapitza","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"2026081311080494300_cit58","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1039\/c5pp00450k","article-title":"A ruthenium(ii) based photosensitizer\nand transferrin complexes enhance\nphoto-physical properties, cell uptake, and photodynamic therapy safety\nand efficacy","volume":"15","author":"Kaspler","year":"2016","journal-title":"Photochem. Photobiol. Sci."},{"issue":"13","key":"2026081311080494300_cit59","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-08-4408","article-title":"A ruthenium-containing\norganometallic compound reduces tumor growth through induction of\nthe endoplasmic reticulum stress gene CHOP","volume":"69","author":"Meng","year":"2009","journal-title":"Cancer Res."},{"issue":"9","key":"2026081311080494300_cit60","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/anie.200906079","article-title":"Characterization\nof a ruthenium(III)\/NAMI-A adduct with bovine serum albumin that exhibits\na high anti-metastatic activity","volume":"49","author":"Liu","year":"2010","journal-title":"Angew. Chem.\nInt. Ed."},{"issue":"10","key":"2026081311080494300_cit61","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1039\/c2mt20072d","article-title":"Distinct cellular fates for KP1019 and NAMI-A determined\nby X-ray fluorescence imaging of single cells","volume":"4","author":"Aitken","year":"2012","journal-title":"Metallomics"},{"issue":"8","key":"2026081311080494300_cit62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale\nand strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026081311080494300_cit63","unstructured":"ALDH1A1 Cell Line Data.\n          . The Human Protein\nAtlas. https:\/\/www.proteinatlas.org\/ENSG00000165092-ALDH1A1\/cell+line (accessed Nov 24, 2025)."},{"key":"2026081311080494300_cit64","unstructured":"ALDH3A1 Cell Line Data.\n          . The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000108602-ALDH3A1\/cell+line (accessed Nov 24, 2025)."},{"issue":"8","key":"2026081311080494300_cit65","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/mnfr.201300684","article-title":"Molecular targets of isothiocyanates\nin cancer: recent advances","volume":"58","author":"Gupta","year":"2014","journal-title":"Mol. Nutr. Food\nRes."},{"issue":"2","key":"2026081311080494300_cit66","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis:\nmolecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"key":"2026081311080494300_cit67","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-207-6","volume-title":"Cell Migration:\nDevelopmental\nMethods and Protocols","author":"Wells","year":"2011"},{"issue":"6","key":"2026081311080494300_cit68","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.neo.2019.03.008","article-title":"ALDH2\nRepression Promotes Lung Tumor Progression via Accumulated\nAcetaldehyde and DNA Damage","volume":"21","author":"Li","year":"2019","journal-title":"Neoplasia"},{"key":"2026081311080494300_cit69","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ejmech.2018.08.007","article-title":"Novel selective\nthiadiazine DYRK1A inhibitor lead scaffold\nwith human pancreatic \u03b2-cell proliferation activity","volume":"157","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"2026081311080494300_cit70","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/ic00004a005","article-title":"Synthesis, molecular structure, and chemical behavior\nof hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III)\nand mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first\nfully characterized chloride-dimethyl sulfoxide-ruthenium(III) complexes","volume":"30","author":"Alessio","year":"1991","journal-title":"Inorg. Chem."},{"key":"2026081311080494300_cit71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinorgbio.2013.07.009","article-title":"Inhibition of human prion neuropeptide\nPrP106\u2013126 aggregation by hexacoordinated ruthenium complexes","volume":"128","author":"Wang","year":"2013","journal-title":"J. Inorg. Biochem."},{"key":"2026081311080494300_cit72","unstructured":"Bruker.\n          ,  SAINT+; Bruker\nAXS Inc.: Madison, Wisconsin, USA, 2007."},{"key":"2026081311080494300_cit73","unstructured":"Sheldrick, G. M.\n          \n          SADABS,\nPrograms Scaling Absorption Correction of Area Detector Data; University of Go\u0308ttingen: Go\u0308ttingen, Germany, 1997."},{"issue":"1","key":"2026081311080494300_cit74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1107\/s2053273314026370","article-title":"SHELXT\u2500integrated\nspace-group and crystal-structure determination","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. A: Found. Adv."},{"issue":"1","key":"2026081311080494300_cit75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure\nrefinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr., Sect.\nC: Struct. Chem."},{"issue":"3","key":"2026081311080494300_cit76","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1083\/jcb.106.3.761","article-title":"Normal keratinization in a spontaneously immortalized\naneuploid human keratinocyte cell line","volume":"106","author":"Boukamp","year":"1988","journal-title":"J. Cell\nBiol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c03490","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/17881\/66238149\/acs.jmedchem.5c03490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/17881\/66238149\/acs.jmedchem.5c03490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:23:32Z","timestamp":1786634612000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/15\/17881\/5231278\/New-Ru-III-NAMI-NAMI-A-Analogue-Complexes-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":76,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,23]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03490","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03490.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03490.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c03490.s003","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}